Core Viewpoint - Sangfor Pharmaceuticals (01530) is experiencing a nearly 5% decline in stock price, currently at HKD 27.76, following the announcement of a share placement to raise approximately HKD 30.87 billion [1] Group 1: Share Placement Details - The company plans to place 105 million shares at a price of HKD 29.62 per share, which represents a 6.50% discount to the previous day's closing price [1] - The shares being placed account for approximately 4.14% of the total issued share capital post-placement [1] - 80% of the funds raised will be allocated for research and development expenses, while the remaining 20% will be used for working capital [1] Group 2: Strategic Developments - In November, Sangfor Pharmaceuticals announced the spin-off of its hair loss treatment subsidiary, Mandi International, for independent listing [1] - According to research from CMB International, the spin-off is expected to provide short-term investment returns for Sangfor Pharmaceuticals [1] - The long-term outlook suggests that the spin-off of the consumer pharmaceutical business will allow the company to focus on its core prescription and innovative drug segments, with the funds raised supporting the commercialization of self-developed innovative products [1]
三生制药现跌近5% 公司近期配股净筹超30亿港元 拟分拆蔓迪国际上市